Profile | GDS2987 / GI_33946273-A |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | ||
GSM215244 | HMVEC_vehicle_rep2 | ||
GSM215253 | HMVEC_vehicle_rep3 | ||
GSM215254 | HMVEC_atorvastatin_rep1 | ||
GSM215282 | HMVEC_atorvastatin_rep3 | 7.2 | 17 |
GSM215344 | HMVEC_atorvastatin_rep2 | 5.4 | 14 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 5.9 | 12 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 19.1 | 37 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 2.9 | 5 |
GSM215294 | HMVEC_SLx2119_rep1 | ||
GSM215295 | HMVEC_SLx2119_rep2 | 5 | 11 |
GSM215296 | HMVEC_SLx2119_rep3 | 23.5 | 37 |
GSM215297 | PASMC_vehicle_rep1 | 24.5 | 36 |
GSM215298 | PASMC_vehicle_rep2 | 24.6 | 36 |
GSM215310 | PASMC_vehicle_rep3 | ||
GSM215311 | PASMC_atorvastatin_rep1 | 8.4 | 15 |
GSM215312 | PASMC_atorvastatin_rep2 | 35.1 | 49 |
GSM215313 | PASMC_atorvastatin_rep3 | 69.1 | 67 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 34.8 | 50 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 86.8 | 73 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 64.5 | 68 |
GSM215327 | PASMC_SLx2119_rep1 | 96.7 | 74 |
GSM215328 | PASMC_SLx2119_rep2 | 57.1 | 66 |
GSM215329 | PASMC_SLx2119_rep3 | 93.1 | 74 |
GSM215330 | Fibroblasts_vehicle_rep1 | 29.8 | 54 |
GSM215331 | Fibroblasts_vehicle_rep2 | 46.2 | 67 |
GSM215332 | Fibroblasts_vehicle_rep3 | 33.6 | 64 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 45.5 | 67 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 50.1 | 68 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 23.9 | 50 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 54.8 | 70 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 42 | 67 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 49 | 68 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 42.1 | 67 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 37.3 | 65 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 37 | 63 |